Selection and Timing of Dose for Each Patient in Clinical Study Report
ICH E3 section 9.4.5 addresses rules or methods used to select the dose and timing of dose for individual patients. This is the patient-level dosing procedure subsection, not the preceding rationale for selecting the study doses or the later results analysis of dose-response relationships.
ReviewedEvidence1 sourceSectionWriting & Style
Quick answer
Describe patient-level dose-selection and dosing-time rules, including titration or adjustment procedures when applicable.
Key details
Core IssueICH E3 section 9.4.5 addresses rules or methods used to select the dose and timing of dose for individual patients.
Registerscholarly, professional, or research/report writing
Important caveats
Scope Boundary
This is the patient-level dosing procedure subsection, not the preceding rationale for selecting the study doses or the later results analysis of dose-response relationships.
Further guidance
Content
Describe patient-level dose-selection and dosing-time rules, including titration or adjustment procedures when applicable.
Purpose
Describe patient-level dose-selection and dosing-time rules, including titration or adjustment procedures when applicable.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
ICH E3 section 12.3.3 calls for analysis and discussion across deaths, other serious adverse events, and other significant adverse events after the relevant case listings and narratives. This is an interpretive synthesis, not a duplicate death/serious-event listing or a replacement for individual patient narratives.
ICH E3 section 11.4.4 addresses relationships among dose, measured drug concentration, and clinical response when those data are relevant to interpreting efficacy. This results-level relationship analysis is distinct from documenting how doses were selected or how concentrations were measured during study conduct.
ICH E3 section 12.4.2 calls for evaluation of each laboratory parameter, with treatment and control groups compared as appropriate and normal laboratory ranges supplied for each analysis. This is the analytical layer under ICH E3 12.4.2; it is distinct from the patient-level raw/listing appendix and from a generic laboratory-data overview.
ICH E3 section 9.4.4 calls for the report to explain how doses used in the study were selected within the treatment plan. Keep dose-selection rationale separate from section 9.4.5, which addresses how dose and dosing time were selected for individual patients.
ICH E3 section 9.3 identifies Selection of Study Population as the investigational-plan section that frames how the study population was selected and leads into inclusion, exclusion, and removal criteria. This is the ICH E3 investigational-plan population-selection section, not the later results description of who was actually enrolled or their demographic/baseline characteristics.
ICH E3 section 11.4.2.1 calls for covariate or prognostic-factor selection and adjustment to be explained, including adjustment methods, analysis results, supportive statistical documentation, and differences from planned analyses when relevant. This results-stage statistical issue is narrower than the general statistical-methods section and should not be used as a substitute for documenting the full analysis plan.
ICH E3 section 12.2.3 calls for analysis of adverse events beyond their tabular display, focusing on patterns important to safety interpretation. Do not treat the analysis as a substitute for the event display or patient-level listing, and do not imply causality beyond what the study evidence supports.
ICH E3 section 9.5.2 calls for discussion of the appropriateness, reliability, or relevance of measurements used to assess efficacy and safety when explanation is needed. This subsection justifies or qualifies measurement choices; it does not replace the section that defines the variables, methods, and timing of assessments.
